Brief: Hansoh Pharmaceutical Says New Drug Application Of "Ibrexafungerp Tablets" Accepted By NMPA
20/07/2023 13:27
July 20 (Reuters) - Hansoh Pharmaceutical Group Company
Ltd 3692.HK :
* NEW DRUG APPLICATION OF "IBREXAFUNGERP TABLETS" ACCEPTED
BY
NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Further company coverage: 3692.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview